An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Open Access
- 15 November 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 112 (10) , 4235-4246
- https://doi.org/10.1182/blood-2007-10-119123
Abstract
TP53 is a tumor suppressor gene that functions as transcriptional regulator influencing cellular responses to DNA damage. Here we explored the clinicKeywords
This publication has 51 references indexed in Scilit:
- High-risk myeloma: a gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasoneBlood, 2008
- CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanismsBlood, 2007
- The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsBlood, 2007
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisBlood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationBlood, 2006
- p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced ApoptosisPublished by Elsevier ,2004
- DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1Oncogene, 2001
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Multiple MyelomaCancer Genetics and Cytogenetics, 2000